HIV-1 envelope-specific B-cell receptor (HIV-1 Env BCR)

Polyclonal B-cell receptors (BCRs) and antibodies specific for HIV-1 envelope (Env) epitopes are the central components of the humoral immune response against HIV-1 (Sok and Burton, 2018). These receptors are expressed on the surface of B lymphocytes and recognize various domains of the HIV-1 Env trimer, including gp120 and gp41 (Haynes et al., 2019). In the context of HIV-1 infection, the natural polyclonal response often fails to neutralize the virus effectively due to rapid viral mutation and the presence of decoy epitopes. However, a subset of these receptors can evolve into broadly neutralizing antibodies (bNAbs) that target conserved sites of vulnerability on the virus. Modern vaccine strategies, such as germline targeting, specifically aim to engage and expand these rare BCR precursors to induce protective immunity (Leggat et al., 2022). Therapeutic interventions also include the passive administration of monoclonal antibodies derived from these polyclonal pools to provide immediate viral suppression. The study of these receptors involves advanced techniques like single-cell BCR sequencing and structural biology to map the interaction between the antibody paratope and the viral epitope (Stamatatos et al., 2021). Safety considerations in modulating these receptors include avoiding the induction of autoreactive antibodies, as some potent HIV-1 antibodies show cross-reactivity with host antigens.

Other names

Anti-HIV-1 Env antibodiesHIV-1 neutralizing antibodiesHIV-1 bNAb precursorsHIV-1 envelope-specific immunoglobulinsHIV-1 Env-specific B-cell repertoire

Immunogens and vaccines act as ligands that bind to specific germline or matured B-cell receptors to initiate signal transduction, leading to B-cell activation, clonal expansion, and the production of high-affinity neutralizing antibodies through somatic hypermutation (Haynes et al., 2019).